PHIOPhio Pharmaceuticals Corp. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 20102
Ticker: PHIO
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2012-05-10
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: PHIO

Detail

Enriched 2026-08-14 20:47

Market cap: $12,546,630
Shares outstanding (class): 11,617,250
Shares outstanding (weighted): 11,617,250
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 6
Location: KING OF PRUSSIA, PA
Homepage: https://www.phiopharma.com
Description: Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Market cap and share counts drift.

Funds holding this security

3 funds · 3 positions · $158.4K reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$97.4K	0.00%	79,853 NS	FIGI
Nomura Healthcare Fund Delaware Group Equity Funds IV	—	$61.0K	0.01%	50,000 NS	FIGI
Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds	—	$4.88	0.00%	4 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERPHIO
FIGI_COMPOSITEBBG0024FKD97
FIGI_SHARE_CLASSBBG0024FKDB4
CIK0001533040
ISINUS71880W5013
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Phio Pharmaceuticals is a biopharmaceutical company developing therapeutics, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.